Interest to use our technology for other cancers

Based on the visibility of preliminary results for GBM, independent groups expressed their strong interest to use the technology for other cancers.

• A Franco-Swiss group of renowned professors will organise a multi centre trial for relapsed patients (80) of adenocarcinoma of the pancreas.
• Two centers in Northern Germany will start a trial for ovarian cancer. Both groups have accepted that all results will belong to ERC and they are committed to finance the studies.
• We are waiting for the approval from the Belgian Authorities to be able to begin an open clinical phase II study with Gliovac/ERC1671/SITOIGANAP.